Recent Antimicrobials Hailed as a 'Turning Point' in Treating Drug-Resistant Gonorrhoea

The initial novel therapies for gonorrhoea in decades are being hailed as a "significant breakthrough" in the fight against increasingly resistant strains of the bacteria, according to scientists.

An International Challenge

The sexually transmitted infection are escalating worldwide, with figures suggesting over 82 million instances per year. Especially elevated rates are seen in Africa and nations within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have hit a historical peak, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely step in the context of growing infection rates, increasing antimicrobial resistance and the highly restricted therapeutic options at this time.”

Health officials are increasingly worried about the surge in drug-resistant strains. The global health body has classified it as a "high-priority threat". Recent surveillance revealed that the effectiveness of standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Therapies Gain Authorization

One new antibiotic, also known as Nuzolvence, was approved by the US FDA in December for use against gonorrhoea. This STI can lead to major issues, including the inability to conceive. Scientists believe that targeted use of this new drug will help delay the development of resistance.

Another new antibiotic, created by the drugmaker GSK, was also approved in close succession. This treatment, which is additionally indicated for urinary tract infections, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

This new treatment was the result of a new, not-for-profit approach for medication research. The charitable organization GARDP worked alongside the drug firm Innoviva to bring it to fruition.

“This authorization signifies a huge turning point in the treatment of highly resistant gonorrhoea, which up to this point has been outpacing medical innovation.”

Testing Outcomes and Global Access

Based on findings released by a prominent scientific publication, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This places it at an comparable level with the current standard treatment, which uses two antibiotics. The trial enrolled nearly 1,000 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, the non-profit has the authority to license and sell the drug in numerous low-income and middle-income countries.

Medical professionals on the front lines have voiced optimism. Access to a single-dose, oral treatment such as this is seen as a "game-changer" for gonorrhoea control. This is considered vital to alleviate the strain of the illness for people and to prevent the spread of highly drug-resistant gonorrhoea worldwide.